<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01028937</url>
  </required_header>
  <id_info>
    <org_study_id>NTK-1</org_study_id>
    <nct_id>NCT01028937</nct_id>
  </id_info>
  <brief_title>Hyperopia Correction Using the NTK Optimal Keratoplasty (Opti-K) System</brief_title>
  <official_title>Hyperopia Correction Using the NTK Optimal Keratoplasty (Opti-K) System</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>NTK Enterprises, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>NTK Enterprises, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this U.S. Clinical Trial on treatment of sighted eyes is to investigate the&#xD;
      safety and effectiveness of optimal keratoplasty (Opti-K™) treatments for hyperopia&#xD;
      correction using the NTK Enterprises (NTK) Opti-K System.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Slow recruitment&#xD;
  </why_stopped>
  <start_date>December 2009</start_date>
  <completion_date type="Actual">January 2018</completion_date>
  <primary_completion_date type="Actual">January 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The Proportion of Eyes (Target: at Least 85%) That Achieve Successful Distance Uncorrected Visual Acuity (D-UCVA) Improvement Defined as 2 Lines (10 Letters) or More Improvement in D-UCVA Following Tx Will be Reported.</measure>
    <time_frame>1 year post-treatment</time_frame>
    <description>The proportion of eyes (target: at least 85%) that achieve successful distance uncorrected visual acuity (D-UCVA) improvement defined as 2 lines (10 letters) or more improvement in D-UCVA following Tx will be reported</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The Proportion of Eyes That Achieve Distance Uncorrected Visual Acuity (D-UCVA) of 20/40 or Better Following Tx and the Proportion of Eyes That Achieve D-UCVA of 20/40 or Better as a Function of the Pre-Tx D-UCVA Will Both be Reported.</measure>
    <time_frame>1 year post-treatment</time_frame>
    <description>The proportion of eyes that achieve distance uncorrected visual acuity (D-UCVA) of 20/40 or better following Tx and the proportion of eyes that achieve D-UCVA of 20/40 or better as a function of the pre-Tx D-UCVA will both be reported.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">6</enrollment>
  <condition>Hyperopia</condition>
  <arm_group>
    <arm_group_label>Hyperopia</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The NTK Optimal Keratoplasty System/Procedure is indicated for the temporary improvement of distance uncorrected visual acuity (in patient eyes that have manifest refraction, spherical equivalent equal to +1.0 to +2.5 Diopters, with less than or equal to 0.75 Diopters of refractive astigmatism (minus cylinder format) and with uncorrected distance visual acuity less than 20/40 but greater than or equal to 20/80. Patients must be at least 40 years of age with a documented stability of refraction for the prior 12 months, as demonstrated by a change of less than or equal to 0.5 Diopters in MRSE. The magnitude of D-UCVA improvement by Opti-K treatment may diminish over time, caused by some regression of effect in addition to natural progressive loss of accommodation and, for most patients, progressive hyperopic shift with increasing age.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Optimal Keratoplasty</intervention_name>
    <description>Laser treatment in 16 spots at treatment energy densities up to 48 mJ per spot</description>
    <arm_group_label>Hyperopia</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Enrollment is limited to subjects who satisfy the following inclusion criteria:&#xD;
&#xD;
               -  Male or Female&#xD;
&#xD;
               -  Any race&#xD;
&#xD;
               -  Patient is at least 40 years old.&#xD;
&#xD;
               -  Patient has bilateral sight with at least one eye with low hyperopia [with +1.0&#xD;
                  to +2.75 D spherical component of manifest refraction, less than or equal to 0.75&#xD;
                  D cylindrical component of manifest refraction (minus cylinder format) and&#xD;
                  manifest refraction, spherical equivalent of +1.0 to +2.5 D].&#xD;
&#xD;
               -  Patient has documented stable refraction defined as a change in baseline MRSE of&#xD;
                  ≤ 0.5 D for the 12 month period prior to primary Opti-K Tx as verified by&#xD;
                  consecutive refractions, medical records or prescription history.&#xD;
&#xD;
               -  Patient is able to tolerate full cycloplegic refraction while not under&#xD;
                  cycloplegia.&#xD;
&#xD;
               -  Patient has distance uncorrected visual acuity (D-UCVA) less than 20/40 and&#xD;
                  better than or equal to 20/80 in both eyes.&#xD;
&#xD;
               -  Patient has stable D-UCVA as documented by a change of ≤ 1 line of D-UCVA for the&#xD;
                  12 month period prior to baseline measurements.&#xD;
&#xD;
               -  Patient has distance and near best spectacle corrected visual acuity (D-BSCVA and&#xD;
                  N-BSCVA) of 20/40 or better in both eyes.&#xD;
&#xD;
               -  Patient has normal videokeratography (i.e., without distorted or unclear corneal&#xD;
                  mires).&#xD;
&#xD;
               -  Contacts lens wearers must:&#xD;
&#xD;
                    1. discontinue use of soft or gas permeable contact lenses at least two weeks&#xD;
                       prior to baseline measurements or discontinue use of hard or rigid gas&#xD;
                       permeable contact lenses at least three weeks prior to baseline measurements&#xD;
                       and&#xD;
&#xD;
                    2. have two central keratometry readings and two manifest refractions taken at&#xD;
                       least one week apart that do not differ by more than 0.5 D in either&#xD;
                       meridian; mires should be regular.&#xD;
&#xD;
               -  Patient is willing and able to comply with all pre-treatment and follow-up&#xD;
                  requirements, including the ability to read English to complete the NEI-RQL&#xD;
                  questionnaire.&#xD;
&#xD;
               -  Patient understands the nature of the procedure, as well as potential\ risks or&#xD;
                  limitations of the treatment, and provides informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients are not permitted to enroll in the study if they meet any of the following&#xD;
             exclusion criteria:&#xD;
&#xD;
               -  Patients with latent hyperopia &gt; 1.0 D (i.e., baseline MRSE and CRSE should not&#xD;
                  differ by more than 1.0 D)&#xD;
&#xD;
               -  Patients with nystagmus&#xD;
&#xD;
               -  Patients with previous intraocular or corneal surgery&#xD;
&#xD;
               -  Patients with any residual, recurrent or active ocular disease or corneal&#xD;
                  abnormality, including any of the following: corneal diameter &lt; 9 mm; central&#xD;
                  corneal thickness &lt; 500 µm; mild to severe dry eye disease; uncontrolled uveitis;&#xD;
                  severe blepharitis; lagophthalmos; glaucoma; intraocular pressure &gt; 21 mm Hg;&#xD;
                  cataract; history of uveitis;corneal shape disorders (keratoconus, keratoglobus,&#xD;
                  pellucid marginal degeneration, significant irregular corneal astigmatism,&#xD;
                  etc.);history of herpes zoster/simplex keratitis&#xD;
&#xD;
               -  Patients with cloudy cornea or cloudy anterior chamber&#xD;
&#xD;
               -  Patients with allergy to anesthetics or postoperative medications&#xD;
&#xD;
               -  Patients with chronic allergic reactions, tearing and/or ocular irritation&#xD;
&#xD;
               -  Patients who are hypersensitive to pain stimulus&#xD;
&#xD;
               -  Patients taking systemic medications (NSAIDs, etc.) that affect wound healing&#xD;
&#xD;
               -  Patients taking amiodarone, isotretinoin and/or sumatriptan&#xD;
&#xD;
               -  Patients requiring administration of topical or systemic ophthalmic medications&#xD;
                  other than the study medications - use of corticosteroids or antimetabolites is&#xD;
                  specifically contraindicated.&#xD;
&#xD;
               -  Patients with a recent history (within one week prior to treatment) of using&#xD;
                  ophthalmic medications containing preservatives (benzalkonium chloride,etc.)&#xD;
                  and/or other ocular drugs that are cytotoxic&#xD;
&#xD;
               -  Patients who are immunocompromised (by, for example, infectious diseases such as&#xD;
                  HIV, herpes, etc. and/or by immunosuppressive medications) or who have autoimmune&#xD;
                  diseases such as lupus, rheumatoid arthritis, etc.&#xD;
&#xD;
               -  Patients with diabetes&#xD;
&#xD;
               -  Pregnant, planning to be pregnant or lactating women&#xD;
&#xD;
               -  Patients with unusual hormonal status due to, for example, hormone replacement&#xD;
                  therapy&#xD;
&#xD;
               -  Patients who have taken or who plan to take oral contraceptives within one year&#xD;
                  prior to, or following, treatment&#xD;
&#xD;
               -  Patients with unrealistic expectations&#xD;
&#xD;
               -  Patients participating in other ophthalmic clinical trials during this clinical&#xD;
                  investigation&#xD;
&#xD;
               -  Persons who, in the determination of the investigator, are not competent to&#xD;
                  understand the procedure or the actions asked of them as research subjects&#xD;
&#xD;
               -  Persons who may not be able to complete the requirements of returning to the&#xD;
                  investigator's clinic over the period of the study, or who may be difficult to&#xD;
                  locate or contact on short notice. This does not preclude vacations or travel.&#xD;
&#xD;
               -  Persons who cannot achieve corneal applanation using the SAWSR device or cannot&#xD;
                  tolerate application of the SAWSR device or who cannot remain motionless for at&#xD;
                  least 5 seconds after verifying proper SAWSR mounting.&#xD;
&#xD;
               -  Patients who are likely to be exposed to high levels of ultraviolet&#xD;
                  radiation(from sunlight, tanning lights, etc.) without protective eyewear during&#xD;
                  the one year period following Opti-K treatment&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nancy Lockerman</last_name>
    <role>Study Director</role>
    <affiliation>NTK Enterprises</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Laser Vision Medical Associates</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90025</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2019</verification_date>
  <study_first_submitted>December 8, 2009</study_first_submitted>
  <study_first_submitted_qc>December 8, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 9, 2009</study_first_posted>
  <results_first_submitted>March 28, 2019</results_first_submitted>
  <results_first_submitted_qc>April 18, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">May 9, 2019</results_first_posted>
  <last_update_submitted>April 18, 2019</last_update_submitted>
  <last_update_submitted_qc>April 18, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">May 9, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Hyperopia correction</keyword>
  <keyword>Laser vision correction</keyword>
  <keyword>Optimal keratoplasty</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hyperopia</mesh_term>
  </condition_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>January 6, 2016</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/37/NCT01028937/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Hyperopia</title>
          <description>The NTK Optimal Keratoplasty System/Procedure is indicated for the temporary improvement of distance uncorrected visual acuity (in patient eyes that have manifest refraction, spherical equivalent equal to +1.0 to +2.5 Diopters, with less than or equal to 0.75 Diopters of refractive astigmatism (minus cylinder format) and with uncorrected distance visual acuity less than 20/40 but greater than or equal to 20/80. Patients must be at least 40 years of age with a documented stability of refraction for the prior 12 months, as demonstrated by a change of less than or equal to 0.5 Diopters in MRSE. The magnitude of D-UCVA improvement by Opti-K treatment may diminish over time, caused by some regression of effect in addition to natural progressive loss of accommodation and, for most patients, progressive hyperopic shift with increasing age.&#xD;
Optimal Keratoplasty: Laser treatment in 16 spots at treatment energy densities up to 48 mJ per spot</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Hyperopia</title>
          <description>Hyperopia treatment</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="6"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="59.8" spread="5.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>The Proportion of Eyes (Target: at Least 85%) That Achieve Successful Distance Uncorrected Visual Acuity (D-UCVA) Improvement Defined as 2 Lines (10 Letters) or More Improvement in D-UCVA Following Tx Will be Reported.</title>
        <description>The proportion of eyes (target: at least 85%) that achieve successful distance uncorrected visual acuity (D-UCVA) improvement defined as 2 lines (10 letters) or more improvement in D-UCVA following Tx will be reported</description>
        <time_frame>1 year post-treatment</time_frame>
        <population>Eyes</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment Group</title>
            <description>Eyes that underwent Opti-K treatment</description>
          </group>
        </group_list>
        <measure>
          <title>The Proportion of Eyes (Target: at Least 85%) That Achieve Successful Distance Uncorrected Visual Acuity (D-UCVA) Improvement Defined as 2 Lines (10 Letters) or More Improvement in D-UCVA Following Tx Will be Reported.</title>
          <description>The proportion of eyes (target: at least 85%) that achieve successful distance uncorrected visual acuity (D-UCVA) improvement defined as 2 lines (10 letters) or more improvement in D-UCVA following Tx will be reported</description>
          <population>Eyes</population>
          <units>Eyes</units>
          <param>Count of Units</param>
          <units_analyzed>Eyes</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Eyes</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Proportion of Eyes That Achieve Distance Uncorrected Visual Acuity (D-UCVA) of 20/40 or Better Following Tx and the Proportion of Eyes That Achieve D-UCVA of 20/40 or Better as a Function of the Pre-Tx D-UCVA Will Both be Reported.</title>
        <description>The proportion of eyes that achieve distance uncorrected visual acuity (D-UCVA) of 20/40 or better following Tx and the proportion of eyes that achieve D-UCVA of 20/40 or better as a function of the pre-Tx D-UCVA will both be reported.</description>
        <time_frame>1 year post-treatment</time_frame>
        <population>1 year follow-up</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment Group</title>
            <description>Eyes that underwent Opti-K treatment</description>
          </group>
        </group_list>
        <measure>
          <title>The Proportion of Eyes That Achieve Distance Uncorrected Visual Acuity (D-UCVA) of 20/40 or Better Following Tx and the Proportion of Eyes That Achieve D-UCVA of 20/40 or Better as a Function of the Pre-Tx D-UCVA Will Both be Reported.</title>
          <description>The proportion of eyes that achieve distance uncorrected visual acuity (D-UCVA) of 20/40 or better following Tx and the proportion of eyes that achieve D-UCVA of 20/40 or better as a function of the pre-Tx D-UCVA will both be reported.</description>
          <population>1 year follow-up</population>
          <units>Eyes</units>
          <param>Count of Units</param>
          <units_analyzed>Eyes</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Eyes</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>1 year</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Hyperopia</title>
          <description>The NTK Optimal Keratoplasty System/Procedure is indicated for the temporary improvement of distance uncorrected visual acuity (in patient eyes that have manifest refraction, spherical equivalent equal to +1.0 to +2.5 Diopters, with less than or equal to 0.75 Diopters of refractive astigmatism (minus cylinder format) and with uncorrected distance visual acuity less than 20/40 but greater than or equal to 20/80. Patients must be at least 40 years of age with a documented stability of refraction for the prior 12 months, as demonstrated by a change of less than or equal to 0.5 Diopters in MRSE. The magnitude of D-UCVA improvement by Opti-K treatment may diminish over time, caused by some regression of effect in addition to natural progressive loss of accommodation and, for most patients, progressive hyperopic shift with increasing age.&#xD;
Optimal Keratoplasty: Laser treatment in 16 spots at treatment energy densities up to 48 mJ per spot</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Nancy Lockerman</name_or_title>
      <organization>NTK Enterprises, Inc.</organization>
      <phone>831-869-1384</phone>
      <email>nlockerman@opti-k.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

